Angiomyogenesis for myocardial repair

Antioxidants and Redox Signaling

Volumn 11, Issue 8, 2009, Pages 1929-1944

  Haider, Husnain Kh ^a   Akbar, Syed Ali ^a   Ashraf, Muhammad ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; GRANULOCYTE COLONY STIMULATING FACTOR; PROTEIN KINASE B; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN 121; VASCULOTROPIN 165; VIRUS VECTOR;

ANGIOGENESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

ANIMALS; GENE THERAPY; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; RATS; STEM CELL TRANSPLANTATION;

ANIMALIA;

EID: 67650251538     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2471     Document Type: Review

References (176)

1. AHA. Heart Disease and Stroke Statistics, 2008 Update. http:// www.americanheart.org/presenter.jhtml?identifier= 3037327
2. Ahmad N, Wang Y, Haider KH, Wang B, Pasha Z, Uzun O, and Ashraf M. Cardiac protection by mitoKATP channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. Am J Physiol Heart Circ Physiol 290: H2402-H2408, 2006.
3. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, and Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972, 1999.
4. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, and Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106: 3009-3017, 2002.
5. Atkins BZ, Hueman MT, Meuchel J, Hutcheson KA, Glower DD, and Taylor DA. Cellular cardiomyoplasty improves diastolic properties of injured heart. J Surg Res 85: 234-242, 1999.
6. Atluri P, Hiesinger W, Gorman RC, Pochettino A, Jessup M, Acker MA, Morris RJ, and Woo YJ. Cardiac re- transplantation is an efficacious therapy for primary cardiac allograft failure. J Cardiothorac Surg 3: 26, 2008.
7. Atluri P and Woo YJ. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs 22:209-222, 2008.
8. Badorff C, Brandes RP, Popp R, Rupp S, Urbich C, Aicher A, Fleming I, Busse R, Zeiher AM, and Dimmeler S. Transdifferentiation of blood-derived human adult endo- thelial progenitor cells into functionally active cardiomyo-cytes. Circulation 107: 1024-1032, 2003.
9. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, and Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428: 668-673, 2004.
10. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E, Varda-Bloom N, Nass D, Engelberg S, and Eldar M. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 22: 2001-2006, 1993.
11. Beck L Jr and D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 11: 365-373, 1997.
12. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bru-neval P, Hagege AA, and Menasche P. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation 108(suppl 1): II247-H252, 2003.
13. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, and Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776, 2003.
14. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, and Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344: 1750-1757, 2001.
15. Bougioukas I, Didilis V, Ypsilantis P, Giatromanolaki A, Sivridis E, Lialiaris T, Mikroulis D, Simopoulos C, and Bougioukas G. Intramyocardial injection of low-dose basic fibroblast growth factor or vascular endothelial growth factor induces angiogenesis in the infarcted rabbit myocardium. Cardiovasc Pathol 16: 63-68, 2007.
16. Brasselet C, Morichetti MC, Messas E, Carrion C, Bissery A, Bruneval P, Vilquin JT, Lafont A, Hagege AA, Menasche P, and Desnos M. Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardium. Eur Heart J 26: 1551-1556, 2005.
17. Bull DA, Bailey SH, Rentz JJ, Zebrack JS, Lee M, Litwin SE, and Kim SW. Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocar- dial infarction: VEGF gene therapy for myocardial infarction. J Control Release 93: 175-181, 2003.
18. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, and Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94: 92-95, 2004.
19. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, Torella D, Tang XL, Rezazadeh A, Kajstura J, Leri A, Hunt G, Varma J, Prabhu SD, Anversa P, and Bolli R. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A 102: 3766-3771, 2005.
20. Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, Buchele D, Anand I, Swingen C, Di Carli MF, Thomas JD, Jaber WA, Opie SR, Campbell A, McCarthy P, Yeager M, Dilsizian V, Griffith BP, Korn R, Kreuger SK, Ghazoul M, MacLellan WR, Fonarow G, Eisen HJ, Dinsmore J, and Diethrich E. Safety and feasibility of autologous myoblast transplantation in patients with is- chemic cardiomyopathy: four-year follow-up. Circulation 112: 1748-1755, 2005.
21. Elmadbouh I, Haider H, Jiang S, Idris NM, Lu G, and Ashraf M. Ex vivo delivered stromal cell-derived factor- 1alpha promotes stem cell homing and induces angio- myogenesis in the infarcted myocardium. J Mol Cell Cardiol 42: 792-803, 2007.
22. Emanueli C and Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br J Pharmacol 133: 951-958, 2001.
23. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237:1-30, 1999.
24. Ferrarini M, Arsic N, Recchia FA, Zentilin L, Zacchigna S, Xu X, Linke A, Giacca M, and Hintze TH. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 98: 954-961, 2006.
25. Floyd SS Jr, Clemens PR, Ontell MR, Kochanek S, Day CS, Yang J, Hauschka SD, Balkir L, Morgan J, Moreland MS, Feero GW, Epperly M, and Huard J. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 5: 19-30, 1998.
26. Fouts K, Fernandes B, Mal N, Liu J, and Laurita KR. Elec- trophysiological consequence of skeletal myoblast transplantation in normal and infarcted canine myocardium. Heart Rhythm 3: 452-461, 2006.
27. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, Weissman NJ, Cerqueira M, Leon MB, and Epstein SE. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. JAm Coll Cardiol 41: 1721-1724, 2003.
28. Fukuda S, Yoshii S, Kaga S, Matsumoto M, Kugiyama K, and Maulik N. Angiogenic strategy for human ischemic heart disease: brief overview. Mol Cell Biochem 264: 143149, 2004.
29. Galinanes M, Loubani M, Davies J, Chin D, Pasi J, and Bell PR. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 13: 7-13, 2004.
30. Gavira JJ, Herreros J, Perez A, Garcia-Velloso MJ, Barba J, Martin-Herrero F, Canizo C, Martin-Arnau A, Marti- Climent JM, Hernandez M, Lopez-Holgado N, Gonzalez- Santos JM, Martin-Luengo C, Alegria E, and Prosper F. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg 131: 799-804, 2006.
31. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, and Hammond HK. Intracoronary gene transfer of fibroblast growth factor- 5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2: 534-539, 1996.
32. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, and Dzau VJ. Evidence supporting paracrine hypothesis for Akt- modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20:661-669,2006.
33. Gojo S, Gojo N, Takeda Y, Mori T, Abe H, Kyo S, Hata J, and Umezawa A. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res 288: 51-59, 2003.
34. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, and Kleiman N. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. JAmCollCardiol42: 1339-1347, 2003.
35. Gyongyosi M, Khorsand A, Zamini S, Sperker W, Streh- blow C, Kastrup J, Jorgensen E, Hesse B, Tagil K, Botker HE, Ruzyllo W, Teresinska A, Dudek D, Hubalewska A, Ruck A, Nielsen SS, Graf S, Mundigler G, Novak J, Sochor H, Maurer G, Glogar D, and Sylven C. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112: I157-I165, 2005.
36. Haider H, Jiang SJ, Lei Y, Law PK, and Sim EKW. Effectiveness of transient immunosuppression using cyclospor- ine for xenomyoblast transplantation for cardiac repair. Transplant Proc 36: 232-235, 2004.
37. Haider H, Ye L, Jiang S, Ge R, Law PK, Chua T, Wong P, and Sim EK. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 82: 539-549, 2004.
38. Haider HK and Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 45: 554-566, 2008.
39. Haider HK, Elmadbouh I, Jean-Baptiste M, and Ashraf M. Nonviral vector gene modification of stem cells for myo- cardial repair. Mol Med 14: 79-86, 2008.
40. Halkos ME, Zhao ZQ, Kerendi F, Wang NP, Jiang R, Schmarkey LS, Martin BJ, Quyyumi AA, Few WL, Kin H, Guyton RA, and Vinten-Johansen J. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myo- cardial infarction. Basic Res Cardiol 103: 525-536, 2008.
41. Hamano K, Li TS, Kobayashi T, Kobayashi S, Matsuzaki M, and Esato K. Angiogenesis induced by the implantation of self-bone marrow cells: a new material for therapeutic an-giogenesis. Cell Transplant 9: 439-443, 2000.
42. Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, and Esato K. Local implantation of autologous bone marrow cells for therapeutic angio- genesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J 65: 845-847, 2001.
43. Haneline LS. Redox regulation of stem and progenitor cells. Antioxid Redox Signal 10: 1849-1852, 2008.
44. Hasegawa T, Kimura A, Miyataka M, Inagaki M, and Ishikawa K. Basic fibroblast growth factor increases regional myocardial blood flow and salvages myocardium in the infarct border zone in a rabbit model of acute myo- cardial infarction. Angiology 50: 487-495, 1999.
45. Hattan N, Warltier D, Gu W, Kolz C, Chilian WM, and Weihrauch D. Autologous vascular smooth muscle cell- based myocardial gene therapy to induce coronary collateral growth. Am J Physiol Heart Circ Physiol 287: H488-H493, 2004.
46. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Niemi- nen MS, Laakso M, and Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107: 2677-2683, 2003.
47. Heilmann C, von Samson P, Schlegel K, Attmann T, von Specht BU, Beyersdorf F, and Lutter G. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 22: 957-964, 2002.
48. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, and McCluskey ER. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107:1359-1365, 2003.
49. Herreros J, Prosper F, Perez A, Gavira JJ, Garcia-Velloso MJ, Barba J, Sanchez PL, Canizo C, Rabago G, Marti- Climent JM, Hernandez M, Lopez-Holgado N, Gonzalez- Santos JM, Martin-Luengo C, and Alegria E. Autologous intramyocardial injection of cultured skeletal muscle- derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 24: 2012-2020, 2003.
50. Hirata Y, Sata M, Motomura N, Takanashi M, Suematsu Y, Ono M, and Takamoto S. Human umbilical cord blood cells improve cardiac function after myocardial infarction. Bio- chem Biophys Res Commun 327: 609-614, 2005.
51. Hodgetts SI, Beilharz MW, Scalzo AA, and Grounds MD. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 9: 489-502, 2000.
52. Horvath KA, Doukas J, Lu CY, Belkind N, Greene R, Pierce GF, and Fullerton DA. Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging. Ann Thorac Surg 74: 481-486, 2002.
53. Hughes GC, Biswas SS, Yin B, Coleman RE, DeGrado TR, Landolfo CK, Lowe JE, Annex BH, and Landolfo KP. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg 77: 812-818, 2004.
54. Jebreel A, England J, Bedford K, Murphy J, Karsai L, and Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88: 271-277, 2007.
55. Jiang S, Haider H, Idris NM, Salim A, and Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 99:776-784, 2006.
56. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, and Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A 95: 8801-8805, 1998.
57. Kajstura J, Rota M, Whang B, Cascapera S, Hosoda T, Bearzi C, Nurzynska D, Kasahara H, Zias E, Bonafe M, Nadal- Ginard B, Torella D, Nascimbene A, Quaini F, Urbanek K, Leri A, and Anversa P. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 96: 127-137, 2005.
58. Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, Bolli R, Anversa P, and Leri A. Cardiac stem cells and myocardial disease. J Mol Cell Cardiol 45: 505-513, 2008.
59. Kardami E, Detillieux K, Ma X, Jiang Z, Santiago JJ, Jimenez SK, and Cattini PA. Fibroblast growth factor-2 and cardi-oprotection. Heart Fail Rev 12: 267-77, 2007.
60. Kawamoto A, Murayama T, Kusano K, Ii M, Tkebuchava T, Shintani S, Iwakura A, Johnson I, von Samson P, Hanley A, Gavin M, Curry C, Silver M, Ma H, Kearney M, and Losordo DW. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110: 1398-1405, 2004.
61. Khan M, Kutala VK, Vikram DS, Wisel S, Chacko SM, Kuppusamy ML, Mohan IK, Zweier JL, Kwiatkowski P, and Kuppusamy P. Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile function. Am J Physiol Heart Circ Physiol 293: H2129-H2139, 2007.
62. Kim BO, Tian H, Prasongsukarn K, Wu J, Angoulvant D, Wnendt S, Muhs A, Spitkovsky D, and Li RK. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation 112: I96-104, 2005.
63. Kim EJ, Li RK, Weisel RD, Mickle DA, Jia ZQ, Tomita S, Sakai T, and Yau TM. Angiogenesis by endothelial cell transplantation. J Thorac Cardiovasc Surg 122: 963-971, 2001.
64. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkh- off D, Wang J, Homma S, Edwards NM, and Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430-46, 2001.
65. Koh GY, Klug MG, Soonpaa MH, and Field LJ. Differentiation and long-term survival of C2C12 myoblast grafts in heart. J Clin Invest 92: 1548-1554, 1993.
66. Kornowski R, Fuchs S, Leon MB, and Epstein SE. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 101: 454-458, 2000.
67. Kudo M, Wang Y, Wani MA, Xu M, Ayub A, and Ashraf M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol 35: 1113-1119, 2003.
68. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, and Simons M. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. JAm Coll Cardiol 36: 2132-2139, 2000.
69. Laham RJ, Post M, Rezaee M, Donnell-Fink L, Wykrzy- kowska JJ, Lee SU, Baim DS, and Sellke FW. Transendo- cardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution. Drug Metab Dispos 33: 1101-1107, 2005.
70. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, and Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100: 1865-1871, 1999.
71. Law PK, Fang G, Chua F, Kakuchaya T, and Bockeria LA. First-in-man myoblast allografts for heart degeneration. Int J Med Implants Devices 1: 100-155, 2003.
72. Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, and Unger EF. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 44:294-302, 1999.
73. Lee JS, Byun J, Kim JM, Kim CY, Kim BM, Chung JH, Jang Y, and Kim DK. Cardiac expression profiles of the naked DNA vectors encoding vascular endothelial growth factor and basic fibroblast growth factor. Exp Mol Med 37: 447-456, 2005.
74. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, and Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102:898-901, 2000.
75. Leor J, Guetta E, Chouraqui P, Guetta V, and Nagler A. Human umbilical cord blood cells: a new alternative for myocardial repair? Cytotherapy 7: 251-257, 2005.
76. Li RK, Jia ZQ, Weisel RD, Merante F, and Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol 31: 513-522, 1999.
77. Li RK, Weisel RD, Mickle DA, Jia ZQ, Kim EJ, Sakai T, Tomita S, Schwartz L, Iwanochko M, Husain M, Cusimano RJ, Burns RJ, and Yau TM. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 119: 62-68, 2000.
78. Liao S, Porter D, Scott A, Newman G, Doetschman T, and Schultz JJ. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J Mol Cell Cardiol 42: 106-120, 2007.
79. Lim SY, Kim YS, Youngkeun AY, Jeong MH, Hong MH, Joo SY, Nam KI, Cho JG, Kang PM, and Park JC. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res 70: 530-542, 2006.
80. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, and Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose- escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105:2012-2018,2002.
81. Lungwitz U, Breunig M, Blunk T, and Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60: 247-266, 2005.
82. Ma N, Stamm C, Kaminski A, Li W, Kleine HD, Muller-Hilke B, Zhang L, Ladilov Y, Egger D, and Steinhoff G. Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice. Cardiovasc Res 66:45-54, 2005.
83. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, and Rosengart TK. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyr- ibonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115: 168-176,1998.
84. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, and Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of in-farcted hearts. Nat Med 9: 1195-1201, 2003.
85. Matsumoto R, Omura T, Yoshiyama M, Hayashi T, In- amoto S, Koh KR, Ohta K, Izumi Y, Nakamura Y, Akioka K, Kitaura Y, Takeuchi K, and Yoshikawa J. Vascular en- dothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 25: 1168-1173, 2005.
86. Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 4: 805-815, 2002.
87. Maulik N and Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. J Mol Cell Cardiol 44: 219-227, 2008.
88. Mazo M, Planat-Benard V, Abizanda G, Pelacho B, Leobon B, Gavira JJ, Penuelas I, Cemborain A, Penicaud L, Laharrague P, Joffre C, Boisson M, Ecay M, Collantes M, Barba J, Casteilla L, and Prosper F. Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur J Heart Fail 10: 454-462, 2008.
89. Menasche P, Alfieri O, Janssens S, McKenna W, Reich- enspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, and Hagege AA. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117: 1189-1200, 2008.
90. Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K, Vilquin JT, and Marolleau JP. Myoblast transplantation for heart failure. Lancet 357: 279-280, 2001.
91. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, and Duboc D. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41: 1078-1083, 2003.
92. Merkle CJ and Montgomery DW. Gene therapy with vascular endothelial growth factor reduces angina. J Cardiovasc Nurs 18: 38-43, 2003.
93. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, and Matsuda H. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 105: 2556-2561, 2002.
94. Miyamoto Y, Suyama T, Yashita T, Akimaru H, and Kurata H. Bone marrow subpopulations contain distinct types of endothelial progenitor cells and angiogenic cytokine-producing cells. J Mol Cell Cardiol 43: 627-635, 2007.
95. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, Long TI, Laird PW, and Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 34: 107-116, 2002.
96. Murry CE, Jennings RB, and Reimer KA. New insights into potential mechanisms of ischemic preconditioning. Circulation 84: 442-445, 1991.
97. Murry CE, Kay MA, Bartosek T, Hauschka SD, and Schwartz SM. Muscle differentiation during repair of myo-cardial necrosis in rats via gene transfer with MyoD. J ClinInvest 98: 2209-2217, 1996.
98. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Naka- jima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, and Field LJ. Haematopoietic stem cells do not transdiffer- entiate into cardiac myocytes in myocardial infarcts. Nature 428: 664-668, 2004.
99. Murry CE, Wiseman RW, Schwartz SM, and Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98: 2512-2523, 1996.
100. Neufeld G and Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 25:373-385, 2006.
101. Niagara MI, Haider H, Jiang S, and Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 100: 545-555, 2007.
102. Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, and van Kuppevelt TH. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 28: 1123-1131, 2007.
103. Ninomiya M, Koyama H, Miyata T, Hamada H, Miyatake S, Shigematsu H, and Takamoto S. Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther 10: 1152-1160, 2003.
104. Ohara N, Koyama H, Miyata T, Hamada H, Miyatake SI, Akimoto M, and Shigematsu H. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther 8: 837-845, 2001.
105. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, and Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705, 2001.
106. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, and Aaronson KD. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: histological analysis of cell survival and differentiation. J Am Coll Cardiol 41: 879-888, 2003.
107. Pagel CN and Morgan JE. Myoblast transfer and gene therapy in muscular dystrophies. Microsc Res Tech 30: 469-479, 1995.
108. Perin E. Transendocardial injection of autologous mononu- clear bone marrow cells in end-stage ischemic heart failure patients: one-year follow-up. Int J Cardiol 95(suppl 1): S45-S46, 2004.
109. Pouzet B, Vilquin JT, Hagege AA, Scorsin M, Messas E, Fiszman M, Schwartz K, and Menasche P. Intramyo- cardial transplantation of autologous myoblasts: can tissue processing be optimized? Circulation 102: III210-III215, 2000.
110. Radke PW, Heinl-Green A, Frass OM, Griesenbach U, Ferrari S, Geddes DM, and Alton EW. Effects of in- tramyocardial pVEGF165 delivery on regional myocardial blood flow: evidence for a spatial "delivery-efficacy" mismatch. Gene Ther 11: 1249-1255, 2004.
111. Rando TA, Pavlath GK, and Blau HM. The fate of myo-blasts following transplantation into mature muscle. Exp Cell Res 220: 383-389; 1995.
112. Reffelmann T, Dow JS, Dai W, Hale SL, Simkhovich BZ, and Kloner RA. Transplantation of neonatal cardiomyo- cytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium. J Mol Cell Cardiol 35: 607-613, 2003.
113. Reinecke H, Poppa V, and Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 34: 241-249, 2002.
114. Reinlib L and Field L. Cell transplantation as future therapy for cardiovascular disease? a workshop of the National Heart, Lung, and Blood Institute. Circulation 101: E182-E187, 2000.
115. Renault MA and Losordo DW. Therapeutic myocardial angiogenesis. Microvasc Res 74: 159-171, 2007.
116. Retuerto MA, Schalch P, Patejunas G, Carbray J, Liu N, Esser K, Crystal RG, and Rosengart TK. Angiogenic pre- treatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg 127: 1041-1049, 2004.
117. Rinsch C, Quinodoz P, Pittet B, Alizadeh N, Baetens D, Montandon D, Aebischer P, and Pepper MS. Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia. Gene Ther 8: 523-533, 2001.
118. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, and Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte- colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 27:1785-1792, 2006.
119. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, and Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468-474, 1999.
120. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, Iaffaldano G, Padin-Iruegas ME, Gonzalez A, Rizzi R, Small N, Muraski J, Alvarez R, Chen X, Urbanek K, Bolli R, Houser SR, Leri A, Sussman MA, and Anversa P. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 104: 17783-17788, 2007.
121. Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maes- troni S, Ferreira-Martins J, Fiumana E, Rastaldo R, Arcarese ML, Mitchell TS, Boni A, Bolli R, Urbanek K, Hosoda T, Anversa P, Leri A, and Kajstura J. Local activation or implantation of cardiac progenitor cells rescues scarred in- farcted myocardium improving cardiac function. Circ Res 103: 107-116, 2008.
122. Rufaihah AJ, Haider HK, Heng BC, Ye L, Toh WS, Tian XF, Lu K, Sim EK, and Cao T. Directing endothelial differentiation of human embryonic stem cells via transduction with an adenoviral vector expressing the VEGF(165) gene. J Gene Med 9: 452-461, 2007.
123. Saeed M, Saloner D, Martin A, Do L, Weber O, Ursell PC, Jacquier A, Lee R, and Higgins CB. Adeno-associated viral vector-encoding vascular endothelial growth factor gene: effect on cardiovascular MR perfusion and infarct resorp- tion measurements in swine. Radiology 243: 451-460, 2007.
124. Sakakibara Y, Nishimura K, Tambara K, Yamamoto M, Lu F, Tabata Y, and Komeda M. Prevascularization with gel-atin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg 124: 50-56, 2002.
125. Schuh A, Liehn EA, Sasse A, Hristov M, Sobota R, Kelm M, Merx MW, and Weber C. Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Res Cardiol 103: 69-77, 2008.
126. Schumacher B, Pecher P, von Specht BU, and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97: 645-650, 1998.
127. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, and Kloner RA. Evaluation of the effects of intramyocardial injection of DNA expressing vascular en- dothelial growth factor (VEGF) in a myocardial infarction model in the rat: angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330, 2000.
128. Schwarz F, Flameng W, Mack B, Turschmann W, Schaper W. Vascular and cardiac contractile reserve in the dog heart with chronic multiple coronary occlusions. Am Heart J 92:600-608, 1976.
129. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, and Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 65: 1540-1544, 1998.
130. Shyu KG, Manor O, Magner M, Yancopoulos GD, and Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98: 2081-2087, 1998.
131. Sim EK, Haider HK, Aziz S, Ooi OC, and Law PK. Myo-blast transplantation on the beating heart. Int Surg 90: 148-50, 2005.
132. Simo R, Carrasco E, Garcia-Ramirez M, and Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71-98, 2006.
133. Simons M. Integrative signaling in angiogenesis. Mol Cell Biochem 264: 99-102, 2004.
134. Siu CW, Moore JC, and Li RA. Human embryonic stem cell-derived cardiomyocytes for heart therapies. Cardiovasc Hematol Disord Drug Targets 7: 145-152, 2007.
135. Stamm C, Kleine HD, Choi YH, Dunkelmann S, and Lauffs JA. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardio-vasc Surg 133: 717-725, 2007.
136. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, and Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361: 45-46, 2003.
137. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kogler G, Wernet P, Muller HW, and Kostering M. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 46: 1651-1658, 2005.
138. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, and Yacoub MH. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 104: I207-1212, 2001.
139. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, and Isner JM. Gene therapy with vascular en- dothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68: 830-836, 1999.
140. Takahashi K, Ito Y, Morikawa M, Kobune M, Huang J, Tsukamoto M, Sasaki K, Nakamura K, Dehari H, Ikeda K, Uchida H, Hirai S, Abe T, and Hamada H. Adenoviral- delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Mol Ther 8: 584-592, 2003.
141. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, and Hamano K. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from is- chemic injury. Am J Physiol Heart Circ Physiol 291: H886-H893, 2006.
142. Takashi E, Wang Y, and Ashraf M. Activation of mito- chondrial K(ATP) channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway. Circ Res 85: 1146-1153, 1999.
143. Tambara K, Sakakibara Y, Sakaguchi G, Lu F, Premaratne GU, Lin X, Nishimura K, and Komeda M. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation 108 Suppl 1: II259-II263, 2003.
144. Thompson RB, van den Bos EJ, Davis BH, Morimoto Y, Craig D, Sutton BS, Glower DD, and Taylor DA. Intracardiac transplantation of a mixed population of bone marrow cells improves both regional systolic contractility and diastolic relaxation. J Heart Lung Transplant 24: 205-214, 2005.
145. Togel F, Hu Z, Weiss K, Isaac J, Lange C, and Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation- independent mechanisms. Am J Physiol Renal Physiol 289:F31-F42, 2005.
146. Toma C, Pittenger MF, Cahill KS, Byrne BJ, and Kessler PD. Human mesenchymal stem cells differentiate to a cardio- myocyte phenotype in the adult murine heart. Circulation 105: 93-98, 2002.
147. Tse HF, Siu CW, Zhu SG, Songyan L, Zhang QY, Lai WH, Kwong YL, Nicholls J, and Lau CP. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur J Heart Fail 9: 747-753, 2007.
148. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Thomas P, Bastian B, Chan JK, Lo G, Ho CL, Chan WS, Kwong RY, Parker A, Hauser TH, Chan J, Fong DY, and Lau CP. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 28: 2998-3005, 2007.
149. Uemura R, Xu M, Ahmad N, and Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98: 1414-1421, 2006.
150. Unger EF, Banai S, Shou M, Lazarous DF, Jaklitsch MT, Scheinowitz M, Correa R, Klingbeil C, and Epstein SE. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 266: H1588-H1595,1994.
151. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, and Quyyumi AA. Effects of a single in- tracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 85: 1414-1419, 2000.
152. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, and Isner JM. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965-974, 2000.
153. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ, Le Jemtel TH, and Alt E. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J 28: 2667-2677, 2007.
154. Villa A, Sanchez PL, and Fernandez-Aviles F. Ventricular arrhythmias following intracoronary bone marrow stem cell transplantation. Europace 9: 1222-1223, 2007.
155. von Degenfeld G, Banfi A, Springer ML, and Blau HM. Myoblast-mediated gene transfer for therapeutic angiogen- esis and arteriogenesis. Br J Pharmacol 140: 620-626, 2003.
156. Walgenbach KJ, Gratas C, Shestak KC, and Becker D. Ischaemia-induced expression of bFGF in normal skeletal muscle: a potential paracrine mechanism for mediating angiogenesis in ischaemic skeletal muscle. Nat Med 1: 453-459, 1995.
157. Wang JS, Shum-Tim D, Chedrawy E, and Chiu RC. The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg 122: 699-705, 2001.
158. Wang M, Tsai BM, Crisostomo PR, and Meldrum DR. Pretreatment with adult progenitor cells improves recovery and decreases native myocardial proinflammatory signaling after ischemia. Shock 25: 454-459, 2006.
159. Wang Y, Haider H, Ahmad N, Zhang D, and Ashraf M. Evidence for ischemia induced host-derived bone marrow cell mobilization into cardiac allografts. J Mol Cell Cardiol 41: 478-487, 2006.
160. Wang Y, Haider HK, Ahmad N, Xu M, Ge R, and Ashraf M. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over- expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 40: 736-745, 2006.
161. Watanabe E, Smith DM Jr, Delcarpio JB, Sun J, Smart FW, Van Meter CH Jr, and Claycomb WC. Cardiomyocyte transplantation in a porcine myocardial infarction model. Cell Transplant 7: 239-246, 1998.
162. Weintraub WS and Sadanandan S. Percutaneous coronary intervention in stable patients after acute myocardial infarction. Circulation 108: 1292-1294, 2003.
163. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lip-polt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, and Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364: 141-148, 2004.
164. Wright MJ, Wightman LM, Lilley C, de Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS, and Marber MS. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 96: 227-236, 2001.
165. Xie X, Cao F, Sheikh AY, Li Z, Connolly AJ, Pei X, Li RK, Robbins RC, and Wu JC. Genetic modification of embryonic stem cells with VEGF enhances cell survival and improves cardiac function. Cloning Stem Cells 9: 549-563, 2007.
166. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, and Ashraf M. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 42: 441-448; 2007.
167. Yau TM, Kim C, Li G, Zhang Y, Fazel S, Spiegelstein D, Weisel RD, and Li RK. Enhanced angiogenesis with mul- timodal cell-based gene therapy. Ann Thorac Surg 83: 1110-1119, 2007.
168. Ye L, Haider H, Jiang S, Ling LH, Ge R, Law PK, and Sim EK. Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. Eur J Heart Fail 7: 945-952, 2005.
169. Ye L, Haider H, Jiang S, Tan RS, Ge R, Law PK, and Sim EK. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 9: 15-22, 2007.
170. Ye L, Haider H, Jiang S, Tan RS, Toh WC, Ge R, and Sim EK. Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies. Eur J Heart Fail 9: 458-465, 2007.
171. Ye L, Haider H, Tan R, Toh W, Law PK, Tan W, Su L, Zhang W, Ge R, Zhang Y, Lim Y, and Sim EK. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation 116: I113-I1120, 2007.
172. Yoo KJ, Li RK, Weisel RD, Mickle DA, Jia ZQ, Kim EJ, Tomita S, and Yau TM. Heart cell transplantation improves heart function in dilated cardiomyopathic hamsters. Circulation 102: III204-III209, 2000.
173. Yoo KJ, Li RK, Weisel RD, Mickle DA, Li G, and Yau TM. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg 70: 859-865, 2000.
174. Yoon YS, Park JS, Tkebuchava T, Luedeman C, and Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 109: 3154-3157, 2004.
175. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, Bieche I, Laurendeau I, Galy-Fauroux I, Fischer AM, and Boisson-Vidal C. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 28:644-650, 2008.
176. Zen K, Okigaki M, Hosokawa Y, Adachi Y, Nozawa Y, Takamiya M, Tatsumi T, Urao N, Tateishi K, Takahashi T, and Matsubara H. Myocardium-targeted delivery of en- dothelial progenitor cells by ultrasound-mediated micro- bubble destruction improves cardiac function via an angiogenic response. J Mol Cell Cardiol 40: 799-809, 2006.